Health Care & Life Sciences » Pharmaceuticals » Top pharmaceutical drugs | Top cancer brands by revenue U.S. 2016

Top U.S. oncology products by revenue in 2016

Leading U.S. oncology brands based on revenue in 2016 (Figures expressed in millions of U.S. dollars, unless otherwise specified)

The data represents the top pharmaceutical chemotherapy and targeted cancer products in the U.S. based on revenues during 2016. Novartis' Gleevec was among the top 10 cancer products in the U.S., generating some 1.2 billion USD in revenue. Cancer risk can increase due to internal or external factors, however, many types of cancers are preventable with a healthy diet, no smoking, and physical activity.

Revlimid (Celgene)	4417
Rituxan (Roche)	3970
Avastin (Roche)	3009
Opdivo (Bristol-Myers Squibb)	2664
Herceptin (Roche)	2547
Ibrance (Pfizer)	2068
Imbruvica (AbbVie)	1580
Xtandi (Astellas)	1218
Gleevec (Novartis)	1214
Alimta (Eli Lilly)	1101
Zytiga (Johnson & Johnson)	1089
Velcade (Takeda)	1044
Sprycel (Bristol-Myers Squibb)	969
Perjeta (Roche)	919
Jakafi (Incyte)	853
Yervoy (Bristol-Myers Squibb)	802
Keytruda (Merck & Co.)	792
Pomalyst (Celgene)	778
Afinitor (Novartis)	775
Tasigna (Novartis)	722
Lupron (AbbVie)	663
Treanda (Cephalon/Teva)	661
Abraxane (Celegene)	634
Erbitux (BMS/Imclone)	581
Tarceva (Roche)	568

Top U.S. oncology products by revenue in 2016

StatInvestor